Few Cardiac Events With Trastuzumab Treatment of Breast CancerFew Cardiac Events With Trastuzumab Treatment of Breast Cancer
Trastuzumab carries only a low risk of cardiotoxicity, a new paper reports. Patients in the study had received one or two years of trastuzumab treatment in the Herceptin Adjuvant (HERA) trial. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Health | Heart | Hematology | Herceptin | Study